Although the European Union has marked solid strides in the way of biosimilars, the overall uptake in individual nations is heavily impacted by domestic policy. A new paper published in PLOS One details some of the initiatives and regulations affecting biosimilars in the E.U. The paper also […]
WHO Commits to Biosimilar Medicine Prequalification Program
The World Health Organization (WHO) is planning on launching a new pilot program, a Biosimilar Medicine Prequalification Program, to assess cheap copies of expensive biotech cancer drugs, making these medicines more widely available. Find out more here. (Source: dispatch tribunal, 5/8/17) […]
The Biosimilars Forum Releases Statement on EMA Information Guide
The Biosimilars Forum recently issued a statement addressing the newly released EMA information guide on biosimilars for healthcare professionals. Hear what they had to say here. (Source: Biosimilars Forum, 5/16/17) […]
US Supreme Court to Weigh in on Biosimilar ‘Patent Dance’
In somewhat of a surprise decision, The US Supreme Court recently decided to to review whether biosimilar companies should have to wait six months after US Food and Drug Administration (FDA) approval before launching their follow-on products. Find out more here. (Source: Zachary Brennan, RAPS, […]
Are Biosimilars the ‘Magic Bullet’ to Drug Prices?
Has American uptake of Biosimilars been too slow? How do payers perceive what's important, and what can companies do to ensure commercial success? Stay ahead in the biosimilars space and download this first word report, Biosimilars: US Payer Perspectives today! […]
Knowledge Gaps Persist for Biosimilars
A recent presentation at the AMCP Annual Meeting gave an update on the latest in biosimilars and discussed the continued knowledge gaps in the health industry surrounding the use of biosimilars. Find out more here. (Source: AMCP) […]
Check Out This Week’s HealthEconomics.Com’s Newsletter
HealthEconomics.Com's weekly newsletter is out! Never worry about missing something big in the news, we take the Top Stories of the week, the most important happenings, and upcoming events and put them together in our weekly newsletter - keeping you up-to-date and in the know! If you would like to […]
The Biosimilar Pipeline is Bursting with Possibilities
Biosimilarpipeline recently reported more than 700 biosimilars currently in development with more than 660 companies involved in the biosimilar land rush. The number of biosimilars in development however, far exceeds the number of agents that will be approved in the near future. Find out more here. […]
Can Pharma get Physicians on Board with Biosimilars?
Payers are enthusiastic about the savings biosimilars bring but warn that physician fear, stoked by a lack of data, clinical inexperience and misinformation, is limiting biosimilar uptake. Take a look at payers candid views of biosimilars in FirstWord's Biosimilars: European Payer Perspectives […]
How Will Pricing Wars Shape the RA Landscape?
In Europe, and soon to be in the US, anti-TNF biosimilars represent the best chance for much needed cost savings in the rheumatoid arthritis (RA) market. Find out how the looming price war will shape the RA landscape in FirstWord's Payer Insight: Rheumatoid Arthritis. (Source: FirstWord, 2017) […]
Take a Virtual Look Inside Biotech Manufacturing
Ever wonder what the inside of a biologic medicines manufacturing facility looks like? Take this virtual tour for a rare look at the highly unique manufacturing facility at Amgen. Step by step, the video takes you through the whole process of product development, all the way to packaging and […]
Check Out This New Specialty Pharma Website
Janssen Biotech, Inc., and Avalere Health recently announced the launch of the new DIMENSIONS website. The site will provide specialty pharmaceutical market stakeholders access to future trends and insights through DIMENSIONS issue briefs, webinars, and data on various topics including:Alternative […]
Payer/Provider Collaboration to Promote Biosimilar Optimization
A panel was convened to share ideas, discuss challenges, and develop practical solutions to promote optimal utilization in order to encourage collaboration between payers and providers to help ensure the success of biosimilar entrants into the marketplace. Learn more here. (Source: Chronis Manolis, […]
Biosimilars – Will the U.S. Ever Catch Up to Europe?
The U.S. Biosimilar market lags almost a decade behind that in Europe. Find 7 key questions asked and answered about the progress made, and what still lies ahead, here. (Source: Dave Picard, Knowledge driven, 8/4/16) […]
2016 – The Future of Biosimilars
A new FirstWord report, The Future of Biosimilars 2016, includes first-hand insight from patient groups, physicians, lawyers, and stakeholders from originator and biosimilar companies. Learn about developers’ market access strategies, originators’ efforts to keep them at bay, key drivers for […]
How Similar are Biosimilars to Branded Counterparts?
This new study finds biosimilar TNF-a inhibitors appear to be comparable to their branded counterparts. Find out more here. (Source: dsn Drug Store News, 2016) […]
Is the U.S. Ready for the Biosimilar Boom?
Biosimilars haven't really taken off in the United States yet, but every industry player wants in. Leading companies, such as Merck are already taking steps to help promote biosimilar acceptance, Find out more here. (Source: Larry Dobrow, MM&M, 5/25/16) […]
Event Highlights From AMCP 2016 Annual Meeting
Cost was a key focus at AMCP 2016, with all members of industry raising a range of questions and concerns for how cost affects pharmaceuticals. See here for a more in depth look at some of the specific discussions and studies that took up the issue of cost within the industry. Following are […]
Specialty Pharmacy Highlights at AMCP Annual Meeting
AMCP recently began their most ambitious specialty pharmacy pre-meeting program, the inaugural Specialty Pharmacy Connect. Learn more here. (Source: Susan Cantrell, Managed Healthcare Executive, 4/18/16) […]
Biosimilars – Ready, Set, Launch
In March of 2015, the AMCP convened a biosimilar Partnership Forum to address current readiness of MCOs, Identify gaps, challenges, and opportunities, and to recommend education and training content. Learn more here. (Source: JMCP, Volume 22 Issue (4), April 2016) […]
Market Access Week in Review
Last week was a good week, full of impactful news on biosimilars and insurer consolidation. Read more here. (Source: DRG- Training, 4/5/16) […]
FDA Releases Draft Guidance on Biosimilar Labeling
The United States Food and Drug Administration (FDA) recently unveiled a 15 page draft guidance on biosimilar labels. Learn more. (Source: Zachary Brennan, RAPS, 3/31/16) […]
How Will Value-Based Pricing Affect Biosimilar Uptake?
Given Big Pharma's increasing attention to value-based deals, this author questions where biosimilars will fit in to it all. Learn more here. (Source: Anna Rose Welch, Bioprocess Online, 3/3/16) […]
15 AMCP Nexus 2016 Sessions Added to AMCP Learn
Are you looking for cutting-edge information on the hottest managed care pharmacy topics of the day, and an opportunity to earn continuing pharmacy education credits? AMCP recently repurposed 15 of its most popular live sessions from AMCP Nexus 2015 as online AMCP Learn programs, available here. […]
What is Driving the Uptake of Biosimilars in Europe?
This First Word report, Biosimilars: European Payer Perspectives (2016), identifies the issues that payers identify as critical to the continued growth and adoption of biosimilars. Available for purchase here. (Source: FirstWord, January 2016) […]
2015 Year in Review for New Medicine Approvals
Last year was an exceptional year for FDA drug approvals with a record 45 new medicines. Read more here. (Source: Holly Campbell, PhRMA, 1/11/16) […]
What Will the FDA Decide on Biosimilars? Payers are Waiting
The Biosimilar market has plenty of hurdles to clear before reaching it's full potential in United States healthcare, and right now, it all seems to be hinging on final guidance from the Food and Drug Administration (FDA). Read more here. (Source: 1/1/16Managed Healthcare Executive, Aine Cryts) […]
What Will Formulary Committees do with Biosimilars?
Formulary committees will have a number of new considerations to keep in mind with the introduction of biosimilar drugs. See 4 factors that should be considered here. (Source: First Report Managed Care, 11/13/15) […]
Biologics & Biosimilars Collective Intelligence Consortium
Managed care organizations have devoted significant resources to develop an infrastructure that makes possible active surveillance of biosimilars in distributed research networks (DRNs). AMCP plans to marshal these resources for the important public health benefit inherit in monitoring biosimilar […]
Biosimilars: Regulatory Outlook
This 64 page report gives in-depth and candid views on what eight industry and biosimilar experts see as the areas that require the most attention within biosimilar regulation. Available for purchase here. (Source: FirstWord, November 2015) […]
